In addition, interrogating the effect of MDX-124 on key oncogenic cell signalling pathways such as PI3K/AKT/mTOR or ERK could further delineate the mechanistic basis of cancer cell growth inhibition we have observed and could provide a rationale for selecting appropriate agents for use in combination therapy studies. The gene discussed is MTOR; the disease is cancer.